title: The role of cetuximab in the treatment of metastatic colorectal cancer.
abstract: Targeted biological therapy is becoming a standard in personalized medicine for patients with advanced stages of cancer. Treatment with cetuximab, an anti-epidermal growth factor receptor (EGFR) antibody, represents an example of personalized anticancer therapy for patients with metastatic colorectal cancer and wild (non-mutated) type of the Kirsten rat sarcoma viral oncogene (KRAS). Here the role of cetuximab in treating metastatic colorectal cancer is discussed with a focus on the treatment of hepatic metastases.
authors.affiliation: Departments of Oncology and Radiotherapy, Charles University Prague, Czech Republic. holubec@fnplzen.cz
authors.forename: Lubos
authors.initials: L
authors.lastname: Holubec
authors.forename: Vaclav
authors.initials: V
authors.lastname: Liska
authors.forename: Vit M
authors.initials: VM
authors.lastname: Matejka
authors.forename: Ondrej
authors.initials: O
authors.lastname: Fiala
authors.forename: Jana
authors.initials: J
authors.lastname: Dreslerova
authors.forename: Petra
authors.initials: P
authors.lastname: Mrazkova
authors.forename: Vladislav
authors.initials: V
authors.lastname: Treska
authors.forename: Jindrich
authors.initials: J
authors.lastname: Finek
mesh_terms: D000911:Antibodies, Monoclonal / Q000627:therapeutic use*; D061067:Antibodies, Monoclonal, Humanized; D000970:Antineoplastic Agents / Q000627:therapeutic use*; D000068818:Cetuximab; D015179:Colorectal Neoplasms / Q000188:drug therapy*; D006801:Humans
chemical_list: D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D000970:Antineoplastic Agents; D000068818:Cetuximab